⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006346 | 0.84 | — | — | |
| SCHEMBL7066423 | 0.84 | ABCC8 (0.31) | — | |
| SCHEMBL7004764 | 0.84 | ABCC8 (0.31) | — | |
| SCHEMBL6791354 | 0.82 | ABCC8 (0.31) | — | |
| SCHEMBL7069047 | 0.82 | — | — | |
| SCHEMBL7171572 | 0.81 | ABCC8 (0.32) | — | |
| SCHEMBL7069196 | 0.79 | ABCC8 (0.33) | — | |
| SCHEMBL7065748 | 0.79 | KDM4E (0.31) | — | |
| SCHEMBL7067993 | 0.79 | ABCC8 (0.33) | — | |
| SCHEMBL7168375 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| EP-0876379-A1 | FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-11-11 | — | — | EP | claimed |
| WO-1997026265-A1 | FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-07-24 | — | — | WO | claimed |
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |